Aptahem AB (publ) (NGM:APTA)

Market Cap	24.22M
Revenue (ttm)	2.47M
Net Income (ttm)	-7.64M
Shares Out	20.97M
EPS (ttm)	-0.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55,857
Average Volume	47,976
Open	1.155
Previous Close	1.150
Day's Range	1.090 - 1.190
52-Week Range	0.560 - 2.400
Beta	0.49
RSI	55.67
Earnings Date	Feb 12, 2026

About Aptahem AB

Aptahem AB (publ), a biotechnology company, develops and sells aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. The company’s lead products candidate is Apta-1, which is in preclinical stage to prevent the onset of life-threatening organ and tissue damage in sepsis patients. It has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Swed...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: APTA

Financial Performance

In 2024, Aptahem AB's revenue was 3.77 million, a decrease of -63.95% compared to the previous year's 10.46 million. Losses were -8.57 million, -22.90% less than in 2023.